Chenel Vanessa, Boissy Patrick, Poirier Marie-Sol, Cloarec Jean-Pierre, Patenaude Johane
Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon, France.
Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.
Int J Nanomedicine. 2015 Mar 16;10:2125-37; quiz 2138-9. doi: 10.2147/IJN.S78799. eCollection 2015.
Despite marked optimism in the field of nanomedicine about the use of drug-delivery nanocarriers, uncertainties exist concerning nanocarriers' possible unintended impacts and effects. These uncertainties could affect user acceptance and acceptability. "Acceptance" refers to the intention to put a technology or a device to a specified use. "Acceptability" refers to a value judgment that accounts for acceptance. The objectives of this study were to characterize impact perception, acceptance, and acceptability in relation to drug-delivery nanocarriers in different contexts of use, and to explore relationships among these concepts.
A sample of European and Canadian researchers and graduate research trainees active in the field of new technologies was recruited by targeted email invitation for participation in a web-based questionnaire study. The questionnaire presented scenarios for two contexts of use (lung cancer, seasonal flu) of drug-delivery nanocarriers with two compositions (carbon, synthetic DNA). Respondents' impact perception, acceptance, and acceptability judgment in relation to each kind of nanocarrier in each context of use were measured with Likert scale questions and scored using categorical values.
Two hundred and fourteen researchers and graduate research trainees completed the questionnaire. The results showed that nanocarrier composition influenced impact perception: as compared with the carbon nanocarrier impact perception, the positive impacts of the synthetic DNA nanocarrier were perceived as more significant and more likely to occur than its negative impacts. Composition did not influence acceptance or acceptability. Context of use significantly influenced acceptance and acceptability of both kinds of nanocarriers: researchers were more likely to accept the use of nanocarriers to treat lung cancer than the seasonal flu. The results also showed a significant relationship between acceptance and the perceived usefulness of the treatments.
Nanocarrier composition does not appear to influence acceptance or acceptability. On the other hand, the nanocarriers' perceived usefulness and context of use are both major factors in accounting for acceptance and acceptability.
尽管纳米医学领域对药物递送纳米载体的应用抱有显著的乐观态度，但纳米载体可能产生的意外影响和作用仍存在不确定性。这些不确定性可能会影响用户的接受度和可接受性。“接受度”指将一项技术或设备用于特定用途的意图。“可接受性”指考虑到接受度的价值判断。本研究的目的是描述在不同使用背景下与药物递送纳米载体相关的影响认知、接受度和可接受性，并探讨这些概念之间的关系。
通过定向电子邮件邀请，招募了活跃于新技术领域的欧洲和加拿大研究人员及研究生作为样本，参与一项基于网络问卷的研究。问卷呈现了两种使用背景（肺癌、季节性流感）下两种成分（碳、合成DNA）的药物递送纳米载体的情景。通过利克特量表问题测量了受访者在每种使用背景下对每种纳米载体的影响认知、接受度和可接受性判断，并使用分类值进行评分。
214名研究人员和研究生完成了问卷。结果表明，纳米载体成分影响影响认知：与碳纳米载体的影响认知相比，合成DNA纳米载体的积极影响被认为比其负面影响更显著且更有可能发生。成分不影响接受度或可接受性。使用背景显著影响两种纳米载体的接受度和可接受性：研究人员更有可能接受使用纳米载体治疗肺癌而非季节性流感。结果还显示接受度与治疗的感知有用性之间存在显著关系。
纳米载体成分似乎不影响接受度或可接受性。另一方面，纳米载体的感知有用性和使用背景都是影响接受度和可接受性的主要因素。
